{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:54:07Z","timestamp":1782341647015,"version":"3.54.5"},"reference-count":88,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025310","name":"National Centre for Clinical Research on Emerging Drugs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100025310","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Investigator Grant","award":["1196560"],"award-info":[{"award-number":["1196560"]}]},{"name":"National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medications Intelligence","award":["1196900"],"award-info":[{"award-number":["1196900"]}]},{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Methamphetamine use disorder is a significant public health concern. No pharmacological treatment options currently exist for methamphetamine use disorder, and psychotherapy is only moderately effective. Preliminary evidence suggests that ketamine-assisted psychotherapy produces sustained improvements in substance use and mental health symptomatology. In addition to direct antidepressant properties, ketamine is hypothesised to increase synaptogenesis and facilitate neuroplasticity, in turn prolonging and enhancing the effects of psychotherapy. Given the withdrawal-associated dysphoria and neurocognitive impairments characterising methamphetamine use disorder, ketamine-assisted psychotherapy may improve the efficacy of psychotherapy alone by addressing these features and facilitating therapeutic engagement. This pilot study aims to investigate the safety and feasibility (time taken to recruit sample, proportion of ineligible participants at pre-screening and screening, number of participants who complete four sessions of psychotherapy, retention rate over full duration of study, acceptability of the intervention) of subanaesthetic ketamine in combination with psychotherapy (cognitive behavioural therapy) for adults with methamphetamine use disorder. Changes in methamphetamine use, cravings and withdrawal, quality of life, and treatment satisfaction will also be explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This is an open-label, single-arm clinical trial. 20 adults meeting DSM-5-TR criteria for methamphetamine use disorder who are seeking to reduce or cease methamphetamine use will be enrolled in the study through a single-site specialist outpatient stimulant treatment service in inner Sydney (St Vincent\u2019s Hospital, Sydney). A 4-week course with three subcutaneous ketamine doses (0.75 mg\/kg to 0.9 mg\/kg, titrated according to tolerability) at weekly intervals and four sessions of cognitive behavioural therapy (one at treatment initiation and three within 24\u201348 hours following each ketamine administration session) will be delivered. Safety and feasibility will be assessed over an 8-week period. Secondary outcomes (changes in methamphetamine use, cravings, withdrawal, quality of life and treatment satisfaction) will be assessed over a 24-week period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study has been approved by the St Vincent\u2019s Hospital Human Research Ethics Committee, reference 2023\/ETH00530. Study findings will be disseminated through articles in scientific, peer-reviewed journals, and at national and international conferences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>ANZCTR: ACTRN12624000895583.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Protocol version<\/jats:title>\n                  <jats:p>The trial protocol (Version 4.0) was approved on 24 June 2024.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092504","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:51:00Z","timestamp":1739177460000},"page":"e092504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-8651","authenticated-orcid":false,"given":"Kathryn","family":"Fletcher","sequence":"first","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-8305","authenticated-orcid":false,"given":"Nadine","family":"Ezard","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-3325","authenticated-orcid":false,"given":"Krista J","family":"Siefried","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"MacDonald","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Acheson","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillinder","family":"Bedi","sequence":"additional","affiliation":[{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Substance Use Research Group, Orygen Ltd, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-3620","authenticated-orcid":false,"given":"Alexandre","family":"Guerin","sequence":"additional","affiliation":[{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Substance Use Research Group, Orygen Ltd, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Knock","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millard","sequence":"additional","affiliation":[{"name":"Clinical Research Unit for Anxiety and Depression, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"May","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brett","sequence":"additional","affiliation":[{"name":"St Vincent's Clinical School; School of Population Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Clinical Pharmacology and Therapeutics, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Doumany","sequence":"additional","affiliation":[{"name":"Australian Injecting and Illicit Drug Users League, Canberra, Canberra, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Exeter, Exeter, Devon, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-9013","authenticated-orcid":false,"given":"Brendan","family":"Clifford","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025101812224569000_15.2.e092504.1","unstructured":"United Nations Office on Drugs and Crime . World drug report 2021. Vienna, 2021. Available: www.unodc.org\/unodc\/en\/data-and-analysis\/wdr2021.html"},{"key":"2025101812224569000_15.2.e092504.2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2174\/1570159X19666210803091637","article-title":"Current and Emerging Treatments for Methamphetamine Use Disorder","volume":"19","author":"Moszczynska","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"2025101812224569000_15.2.e092504.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00471.x"},{"key":"2025101812224569000_15.2.e092504.4","first-page":"1","article-title":"The experience of methamphetamine use disorder and the negative consequences of relapse \u2013 a qualitative study","volume":"0","author":"Klein","year":"2023","journal-title":"J Addict Diseases"},{"key":"2025101812224569000_15.2.e092504.5","unstructured":"Alcohol, tobacco & other drugs in Australia. Australian Institute of Health and Welfare; 2024."},{"key":"2025101812224569000_15.2.e092504.6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/07067437221083505","article-title":"Continuing Increase in Stimulant Dependence \u2013 Time to Implement Medical Treatment","volume":"67","author":"Bisaga","year":"2022","journal-title":"Can J Psychiatry"},{"key":"2025101812224569000_15.2.e092504.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301481"},{"key":"2025101812224569000_15.2.e092504.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044696","article-title":"Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study","volume":"11","author":"Ezard","year":"2021","journal-title":"BMJ Open"},{"key":"2025101812224569000_15.2.e092504.9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08020304"},{"key":"2025101812224569000_15.2.e092504.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00711-x"},{"key":"2025101812224569000_15.2.e092504.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020214"},{"key":"2025101812224569000_15.2.e092504.12","doi-asserted-by":"publisher","DOI":"10.1080\/09595230801919494"},{"key":"2025101812224569000_15.2.e092504.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96912797.x"},{"key":"2025101812224569000_15.2.e092504.14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/dar.12528","article-title":"Predicting abstinence from methamphetamine use after residential rehabilitation: Findings from the Methamphetamine Treatment Evaluation Study","volume":"37","author":"McKetin","year":"2018","journal-title":"Drug Alcohol Rev"},{"key":"2025101812224569000_15.2.e092504.15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1360-0443.2007.01768.x","article-title":"Predicting in-treatment performance and post-treatment outcomes in methamphetamine users","volume":"102","author":"Hillhouse","year":"2007","journal-title":"Addiction"},{"key":"2025101812224569000_15.2.e092504.16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/npp.2015.191","article-title":"Withdrawal from Acute Amphetamine Induces an Amygdala-Driven Attenuation of Dopamine Neuron Activity: Reversal by Ketamine","volume":"41","author":"Belujon","year":"2016","journal-title":"Neuropsychopharm"},{"key":"2025101812224569000_15.2.e092504.17","doi-asserted-by":"crossref","first-page":"109846","DOI":"10.1016\/j.drugalcdep.2023.109846","article-title":"Proof-of-concept trial of Goal Management Training+ to improve executive functions and treatment outcomes in methamphetamine use disorder","volume":"246","author":"Anderson","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"2025101812224569000_15.2.e092504.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025101812224569000_15.2.e092504.19","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S360733"},{"key":"2025101812224569000_15.2.e092504.20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jad.2022.07.030","article-title":"Active mechanisms of ketamine-assisted psychotherapy: A systematic review","volume":"315","author":"Joneborg","year":"2022","journal-title":"J Affect Disord"},{"key":"2025101812224569000_15.2.e092504.21","first-page":"566","article-title":"Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2025101812224569000_15.2.e092504.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.06.039"},{"key":"2025101812224569000_15.2.e092504.23","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.16"},{"key":"2025101812224569000_15.2.e092504.24","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review","volume":"9","author":"Jones","year":"2018","journal-title":"Front Psychiatry"},{"key":"2025101812224569000_15.2.e092504.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"2025101812224569000_15.2.e092504.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03066.x"},{"key":"2025101812224569000_15.2.e092504.27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"2025101812224569000_15.2.e092504.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.017"},{"key":"2025101812224569000_15.2.e092504.29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2019.10728","article-title":"Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine","volume":"322","author":"Wilkinson","year":"2019","journal-title":"JAMA"},{"key":"2025101812224569000_15.2.e092504.30","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62"},{"key":"2025101812224569000_15.2.e092504.31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392"},{"key":"2025101812224569000_15.2.e092504.32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am J Psychiatry"},{"key":"2025101812224569000_15.2.e092504.33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19070684"},{"key":"2025101812224569000_15.2.e092504.34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.21030277"},{"key":"2025101812224569000_15.2.e092504.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(02)00275-1"},{"key":"2025101812224569000_15.2.e092504.36","doi-asserted-by":"publisher","DOI":"10.1159\/000517074"},{"key":"2025101812224569000_15.2.e092504.37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025101812224569000_15.2.e092504.38","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2025101812224569000_15.2.e092504.39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2025101812224569000_15.2.e092504.40","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.6.885"},{"key":"2025101812224569000_15.2.e092504.41","unstructured":"Baxter . Australian product information ketamine - baxter (ketamine hydrochloride) solution for injection. 2020. Available: http:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2018-PI-02521-1"},{"key":"2025101812224569000_15.2.e092504.42","unstructured":"Pfizer . Australian product information \u2013 ketalar(R)(ketamine hydrochloride). 2021. Available: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2020-PI-02094-1"},{"key":"2025101812224569000_15.2.e092504.43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jad.2022.04.020","article-title":"The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry","volume":"308","author":"Bayes","year":"2022","journal-title":"J Affect Disord"},{"key":"2025101812224569000_15.2.e092504.44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br J Psychiatry"},{"key":"2025101812224569000_15.2.e092504.45","unstructured":"Baker A , Kay-Lambkin F , Lee NK , et al . A brief cognitive behavioural intervention for regular amphetamine users. A treatment guide. Canberra: Australian Government Department of Health and Ageing; 2003. Available: https:\/\/www.drugsandalcohol.ie\/13632\/"},{"key":"2025101812224569000_15.2.e092504.46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2044.1981.tb08721.x","article-title":"Adverse reactions to ketamine anaesthesia. Abolition by a psychological technique","volume":"36","author":"Sklar","year":"1981","journal-title":"Anaesthesia"},{"key":"2025101812224569000_15.2.e092504.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.08.009"},{"key":"2025101812224569000_15.2.e092504.48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2016.39","article-title":"Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial","volume":"22","author":"Dakwar","year":"2017","journal-title":"Mol Psychiatry"},{"key":"2025101812224569000_15.2.e092504.49","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use annotated with TGA comments. In: integrated addendum to ICH E6(R1): guideline for good clinical practice ICH E6(R2). 2016. Available: https:\/\/www.tga.gov.au\/resources\/publication\/publications\/ich-guideline-good-clinical-practice"},{"key":"2025101812224569000_15.2.e092504.50","unstructured":"National Health and Medical Research Council . Safety monitoring and reporting in clinical trials involving therapeutic goods. 2016. Available: https:\/\/www.nhmrc.gov.au\/about-us\/publications\/safety-monitoring-and-reporting-clinical-trials-involving-therapeutic-goods"},{"key":"2025101812224569000_15.2.e092504.51","unstructured":"US Department of Health and Human Services . Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events corrected version 2.1. 2017. Available: https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/grading-severity-adult-pediatric-adverse-events-corrected-version-two-one"},{"key":"2025101812224569000_15.2.e092504.52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.119","article-title":"A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions","volume":"282","author":"Rodrigues","year":"2021","journal-title":"J Affect Disord"},{"key":"2025101812224569000_15.2.e092504.53","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"2025101812224569000_15.2.e092504.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.07.035"},{"key":"2025101812224569000_15.2.e092504.55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuropharm.2014.04.014","article-title":"Human abuse liability evaluation of CNS stimulant drugs","volume":"87","author":"Romach","year":"2014","journal-title":"Neuropharmacology"},{"key":"2025101812224569000_15.2.e092504.56","doi-asserted-by":"publisher","DOI":"10.1037\/a0030992"},{"key":"2025101812224569000_15.2.e092504.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2010.10.008"},{"key":"2025101812224569000_15.2.e092504.58","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215588242"},{"key":"2025101812224569000_15.2.e092504.59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01002.x"},{"key":"2025101812224569000_15.2.e092504.60","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-015-0026-y","article-title":"Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers","volume":"1","author":"O\u2019Cathain","year":"2015","journal-title":"Pilot Feasibility Stud"},{"key":"2025101812224569000_15.2.e092504.61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00132576-200211000-00005","article-title":"A Comparison of Single-Item Visual Analog Scales With a Multiitem Likert-Type Scale for Assessment of Cocaine Craving in Persons With Bipolar Disorder","volume":"1","author":"Lee","year":"2002","journal-title":"Addict Disord Their Treat"},{"key":"2025101812224569000_15.2.e092504.62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.1999.00517.x"},{"key":"2025101812224569000_15.2.e092504.63","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000018486.91360.00"},{"key":"2025101812224569000_15.2.e092504.64","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-1"},{"key":"2025101812224569000_15.2.e092504.65","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7189(79)90094-6"},{"key":"2025101812224569000_15.2.e092504.66","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2025101812224569000_15.2.e092504.67","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"2025101812224569000_15.2.e092504.68","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOBA.0000007455.08539.94"},{"key":"2025101812224569000_15.2.e092504.69","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2025101812224569000_15.2.e092504.70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.drugpo.2018.03.020","article-title":"Substance Use and Sex Index (SUSI): First stage development of an assessment tool to measure behaviour change in sexualised drug use for substance use treatment studies","volume":"55","author":"Ezard","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025101812224569000_15.2.e092504.71","doi-asserted-by":"publisher","DOI":"10.2307\/1384454"},{"key":"2025101812224569000_15.2.e092504.72","doi-asserted-by":"crossref","unstructured":"Quinn ME , Joormann J . Executive control under stress: Relation to reappraisal ability and depressive symptoms. Behav Res Ther 2020;131. doi:10.1016\/j.brat.2020.103634","DOI":"10.1016\/j.brat.2020.103634"},{"key":"2025101812224569000_15.2.e092504.73","doi-asserted-by":"publisher","DOI":"10.1002\/nur.20247"},{"key":"2025101812224569000_15.2.e092504.74","unstructured":"National Health and Medical Research Council . Payment of participants in research: information for researchers, HRECs and other ethics review bodies. 2019. Available: https:\/\/www.nhmrc.gov.au\/about-us\/publications\/payment-participants-research-information-researchers-hrecs-and-other-ethics-review-bodies"},{"key":"2025101812224569000_15.2.e092504.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025101812224569000_15.2.e092504.76","unstructured":"Clinical Trials Project Reference Group . National standard operating procedures for clinical trials, including teletrials, in Australia. Australian Government Department of Health and Aged Care; 2020. Available: https:\/\/www.health.gov.au\/resources\/publications\/national-standard-operating-procedures-for-clinical-trials?language=en"},{"key":"2025101812224569000_15.2.e092504.77","unstructured":"IBM Corp . IBM spss statistics for windows (version 29.0). Armonk, NY IBM Corp; 2023."},{"key":"2025101812224569000_15.2.e092504.78","doi-asserted-by":"publisher","DOI":"10.1080\/17437199.2022.2161594"},{"key":"2025101812224569000_15.2.e092504.79","unstructured":"QSR International Pty Ltd . NVivo (version 14) [computer software]. QSR International Pty Ltd; 2023."},{"key":"2025101812224569000_15.2.e092504.80","unstructured":"National Health and Medical Research Council . National statement on ethical conduct in human research 2007 (updated may 2015). Canberra Australian Government; 2015."},{"key":"2025101812224569000_15.2.e092504.81","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-015-0231-7","article-title":"Quality of life improved following in-patient substance use disorder treatment","volume":"13","author":"Pasareanu","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025101812224569000_15.2.e092504.82","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"2025101812224569000_15.2.e092504.83","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/00952990.2016.1278449","article-title":"Ketamine and international regulations","volume":"43","author":"Liao","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2025101812224569000_15.2.e092504.84","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1025726","article-title":"The economics of psychedelic-assisted therapies: A research agenda","volume":"13","author":"Marseille","year":"2022","journal-title":"Front Psychiatry"},{"key":"2025101812224569000_15.2.e092504.85","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/00048674241237094","article-title":"Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic","volume":"58","author":"Thornton","year":"2024","journal-title":"Aust N Z J Psychiatry"},{"key":"2025101812224569000_15.2.e092504.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.04.035"},{"key":"2025101812224569000_15.2.e092504.87","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2022.5","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review - CORRIGENDUM","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych Open"},{"key":"2025101812224569000_15.2.e092504.88","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/00048674241242315","article-title":"Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand","volume":"58","author":"Carroll","year":"2024","journal-title":"Aust N Z J Psychiatry"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:22:59Z","timestamp":1760815379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-092504"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092504","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}